Cagrilintide is a long-acting synthetic analogue of amylin, a hormone co-secreted with
insulin by pancreatic beta cells. It is primarily investigated for the treatment of obesity and
type 2 diabetes due to its effects on appetite regulation, gastric emptying, and glycemic
control.
Once-weekly dosing potential due to extended half-life
Appetite suppression and improved satiety
Potential for enhanced weight loss when combined with GLP-1 receptor agonists
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Cagrilintide is a long-acting synthetic analogue of amylin, a hormone co-secreted with insulin by pancreatic beta cells.
We are committed to supplying high-quality GMP products with logistics according to GDP regulations.
Cagrilintide mimics the physiological actions of amylin. It slows gastric emptying, which
delays nutrient absorption and promotes early satiety, helping reduce food intake. It also
suppresses glucagon secretion, reducing hepatic glucose production, and modulates
central appetite control mechanisms. The sustained receptor activation provided by its
long-acting formulation supports improved metabolic regulation, particularly when used
alongside other metabolic agents.
The extended half-life of Cagrilintide supports once-weekly administration, which can
improve patient adherence in clinical use. Its mechanism addresses multiple aspects of
metabolic dysfunction, including appetite control and postprandial glucose regulation.
When combined with GLP-1 receptor agonists, it has shown additive effects on weight loss
and glycemic parameters. The API is produced to GMP standards, ensuring consistent
quality suitable for pharmaceutical formulation and compounding purposes.
Commonly observed side effects are consistent with those of amylin analogues and GLP-1
receptor agonists and may include mild to moderate nausea, gastrointestinal discomfort,
and injection site reactions. Hypoglycemia is uncommon but may occur, particularly when
used in combination with insulin or other glucose-lowering drugs. Clinical monitoring is
recommended during treatment initiation.
Cagrilintide is a promising long-acting amylin analogue under development for obesity and
type 2 diabetes treatment. Its pharmacological profile offers potential benefits in appetite
regulation and glycemic control. The availability of GMP-grade Cagrilintide API facilitates
research, formulation, and compounding efforts within the pharmaceutical industry.
“Medicapharma’s products and services are exclusively available to licensed companies and professionals. We do not sell to individuals or private consumers.”
